OGIVRI Q Code: Q5114

Drug & Product Overview

HCPCS Descriptor Injection, trastuzumab-dkst, biosimilar, (ogivri), 10 mg

HCPCS Added Date July 1, 2019

Manufacturer Biocon Biologics Inc

Route of Administration Intravenous

Generic Status Single-Source; Branded

Dosage Type Single-Dose, Multi-Dose

Dosage Form Injection, Powder, Lyophilized, For Solution | Kit

About OGIVRI

Ogivri is a medication aligned to the HCPCS Q Code: Q5114 for billing, pricing, and reimbursement purposes in the United States. This Oncology medication is administered via the intravenous route and manufactured by Biocon Biologics Inc.

According to CMS Drug Use Information: Trastuzumab is used to treat certain types of breast, stomach, or esophagus cancer. Trastuzumab belongs to a class of medications known as monoclonal antibodies. It works by slowing or stopping the growth of cancer cells. This monograph is about the following trastuzumab products: trastuzumab, trastuzumab-anns, trastuzumab-dkst, trastuzumab-dttb, trastuzumab-pkrb, trastuzumab-qyyp, trastuzumab-strf.

Disclaimer: This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your healthcare professional.

NDC Code Information

Based on publicly available CMS files. The list of NDCs below is not exhaustive.

NDC Code	Drug	Manufacturer	Billing Units / Pkg	Package Size
67457-0847-44	Ogivri	Mylan Institutional LLC	42	Kit
67457-0991-15	Ogivri	Mylan Institutional LLC	15	150 MG / 7.4 ML
83257-0001-11	Ogivri	Biocon Biologics Inc.	15	150 MG / 7.4 ML
83257-0004-12	Ogivri	Biocon Biologics Inc.	42	Kit

Login for the full NDC crosswalk View pricing, complete NDC-to-HCPCS alignments, and package details.

Login →

OGIVRI Pricing & Reimbursement

Q5114 Private Payer Reimbursement

$40.06 / HCPCS unit as of Jan 2026

National median reimbursement across major commercial payers.

Create an account on PayerPrice for more information →

Historical Graphing and Billing Calculator

per HCPCS unit

As of Q3 2026

Trastuzumab Biosimilar Information:

OGIVRI Approval Date: December 1, 2017

Product Name	HCPCS Code	Active Ingredient	BLA Type
Herceptin	J9355	Trastuzumab	351(a) Originator Product
Ogivri	Q5114	Trastuzumab	351(k) Biosimilar
Herzuma	Q5113	Trastuzumab	351(k) Biosimilar
Ontruzant	Q5112	Trastuzumab	351(k) Biosimilar
Trazimera	Q5116	Trastuzumab	351(k) Biosimilar
Kanjinti	Q5117	Trastuzumab	351(k) Biosimilar
Hercessi	Q5146	Trastuzumab	351(k) Biosimilar

OGIVRI Claims Performance

Claims from Jan 2026 – Aug 2026

Claim Denial Rate 10.12%

Avg. Days to File 7.4days

Avg. Days to Pay 22.4days

Real-world claims performance from FocalPoint, OnPoint Oncology's reimbursement analytics platform, with claims data accrued at the clearing house level.

Explore Q5114 claims analytics on FocalPoint →

OGIVRI CPT Administration Codes

CPT Code	Description
96413	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug
96415	Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)

Not on the CMS JW / JZ list

CMS does not include Ogivri (Q5114) on its list of HCPCS pertaining to single-dose containers. Per CMS guidelines, the JZ/JW wastage modifiers may not apply when billing Q5114. Wastage billing guide →

OGIVRI Medically Unlikely Edits (MUE)

The most billing units of Q5114 Medicare will pay for one patient in one day, as published by CMS. 1 unit = 10 mg.

Practitioner Office & Hospital Outpatient

120 units / day

= 1,200 mg per day

MAI 3 · Date of Service Edit: Clinical. Per-day limit based on clinical expectations; excess units are denied but may be appealed with documentation of medical necessity. See all MUE limits →

OGIVRI Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

Breast Cancer Gastric or Gastroesophageal Junction Adenocarcinoma Metastatic Breast Cancer Metastatic Gastric Cancer

Drug Class

HER2/Neu/cerbB2 Antagonists [MoA]HER2/neu Receptor Antagonist [EPC]

Frequently Asked Questions

Is there an available Ogivri billing and coding guide?

Our team has not identified a manufacturer-published source of billing and coding information for OGIVRI.

Are there any available Ogivri patient assistance programs?

OGIVRI patient assistance information can be found through Biocon Biologics Inc. Visit Here →

Where can I find Ogivri prescribing information?

OGIVRI prescribing information can be found at the link below. Please reach out to us if you believe this information to be innacurate or out of date. Visit Here →

Where can I find Ogivri side effect information?

Our team has not yet identified a source of side effects information for OGIVRI. Please check back in a few weeks.

Does billing OGIVRI require JZ/JW wastage modifiers?

CMS does not include OGIVRI (Q5114) on its list of HCPCS pertaining to single-dose containers. Per CMS guidelines, the JZ/JW wastage modifiers may not apply when billing Q5114. For more information, visit the link below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.